ze:ro Praxen MVZ fuer Nierenerkrankungen und Bluthochdruck GmbH Mannheim — Clinical Trial Site

9 Registered trials

5 Currently recruiting

Organisation

ze:ro Praxen MVZ fuer Nierenerkrankungen und Bluthochdruck GmbH Mannheim

Location

Mannheim, Germany

Identifier

ORG-100045952

Address

Georg-Lechleiter-Platz 3, Schwetzingerstadt, 68165, Germany

Departments

#1417: Praxis für Kardiologie und Pneumologie
#3465
2202: MVZ für Nierenerkrankungen/ Bluthochdruck
3465: Praxis fuer Kardiologie
Kardiologie - Angiologie - Pneumologie
NA
Practice
Praxis für Innere Medizin, Kardiologie, Angiologie, Pneumologie und Allergologie
Ze:ro Praxen

Clinical trials at this site (9)

Search interface

An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting

2024-516356-18-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-02-17
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig… Recruiting

2025-520519-14-00 Atherosclerotic Cardiovascular Disease 5 2025-09-03
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on… Recruiting

2022-502135-19-00 Calcific Aortic Valve Stenosis 4 2024-07-18
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit… Ended

2023-508292-37-00 Cardiovascular Disease 5 2020-03-06